295 related articles for article (PubMed ID: 24396518)
1. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Yang L; Sajja HK; Cao Z; Qian W; Bender L; Marcus AI; Lipowska M; Wood WC; Wang YA
Theranostics; 2013; 4(1):106-18. PubMed ID: 24396518
[TBL] [Abstract][Full Text] [Related]
2. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging.
Tan Y; Cao Z; Sajja HK; Lipowska M; Wang YA; Yang L; Jiang H
J Xray Sci Technol; 2013; 21(1):43-52. PubMed ID: 23507851
[TBL] [Abstract][Full Text] [Related]
3. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
Yang L; Mao H; Cao Z; Wang YA; Peng X; Wang X; Sajja HK; Wang L; Duan H; Ni C; Staley CA; Wood WC; Gao X; Nie S
Gastroenterology; 2009 May; 136(5):1514-25.e2. PubMed ID: 19208341
[TBL] [Abstract][Full Text] [Related]
5. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Lee GY; Qian WP; Wang L; Wang YA; Staley CA; Satpathy M; Nie S; Mao H; Yang L
ACS Nano; 2013 Mar; 7(3):2078-89. PubMed ID: 23402593
[TBL] [Abstract][Full Text] [Related]
6. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Christensen A; Juhl K; Persson M; Charabi BW; Mortensen J; Kiss K; Lelkaitis G; Rubek N; von Buchwald C; Kjær A
Oncotarget; 2017 Feb; 8(9):15407-15419. PubMed ID: 28039488
[TBL] [Abstract][Full Text] [Related]
7. Receptor-targeted nanoparticles for in vivo imaging of breast cancer.
Yang L; Peng XH; Wang YA; Wang X; Cao Z; Ni C; Karna P; Zhang X; Wood WC; Gao X; Nie S; Mao H
Clin Cancer Res; 2009 Jul; 15(14):4722-32. PubMed ID: 19584158
[TBL] [Abstract][Full Text] [Related]
8. Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.
Xi L; Grobmyer SR; Zhou G; Qian W; Yang L; Jiang H
J Biophotonics; 2014 Jun; 7(6):401-9. PubMed ID: 23125139
[TBL] [Abstract][Full Text] [Related]
9. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla MO; Karna P; Sajja HK; Mao H; Yates C; Turner T; Aneja R
J Control Release; 2011 Feb; 149(3):314-22. PubMed ID: 21047537
[TBL] [Abstract][Full Text] [Related]
10. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts.
Kurbegovic S; Juhl K; Sørensen KK; Leth J; Willemoe GL; Christensen A; Adams Y; Jensen AR; von Buchwald C; Skjøth-Rasmussen J; Ploug M; Jensen KJ; Kjaer A
Theranostics; 2021; 11(15):7159-7174. PubMed ID: 34158842
[TBL] [Abstract][Full Text] [Related]
11. Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105.
Juhl K; Christensen A; Persson M; Ploug M; Kjaer A
PLoS One; 2016; 11(2):e0147428. PubMed ID: 26828431
[TBL] [Abstract][Full Text] [Related]
12. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors.
Baart VM; van Manen L; Bhairosingh SS; Vuijk FA; Iamele L; de Jonge H; Scotti C; Resnati M; Cordfunke RA; Kuppen PJK; Mazar AP; Burggraaf J; Vahrmeijer AL; Sier CFM
Mol Imaging Biol; 2023 Feb; 25(1):122-132. PubMed ID: 34642899
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
14. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Gurka MK; Pender D; Chuong P; Fouts BL; Sobelov A; McNally MW; Mezera M; Woo SY; McNally LR
J Control Release; 2016 Jun; 231():60-7. PubMed ID: 26763377
[TBL] [Abstract][Full Text] [Related]
15. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
Liu D; Overbey D; Watkinson L; Giblin MF
Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
[TBL] [Abstract][Full Text] [Related]
17. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
18. Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery.
Kurbegovic S; Juhl K; Chen H; Qu C; Ding B; Leth JM; Drzewiecki KT; Kjaer A; Cheng Z
Bioconjug Chem; 2018 Nov; 29(11):3833-3840. PubMed ID: 30296054
[TBL] [Abstract][Full Text] [Related]
19. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
20. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
O'Halloran TV; Ahn R; Hankins P; Swindell E; Mazar AP
Theranostics; 2013; 3(7):496-506. PubMed ID: 23843897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
